Paper Details

  1. Home
  2. Paper Details

Comparative immunogenicity and tolerance of Vaqta and Havrix.

Author: BraconierJ H, NorrbyS R, WennerholmS

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Two inactivated hepatitis A vaccines, Vaqta and Havrix, were compared in a randomized trial of 520 adults. Vaqta was found to have better local tolerance than Havrix, with similar immunogenicity and systemic tolerance.
Paper Details　
Original Abstract of the Article :
In an open-label, randomised trial, 520 adults of both sexes aged 18-30 years were allocated to receive one of two inactivated hepatitis A vaccines; Vaqta or Havrix, at 0 and 24 weeks. Doses used were 50 or 100 antigen units (U) of Vaqta and 1440 enzyme linked immunosorbent assay U of Havrix given a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0264-410x(98)00352-1

データ提供：米国国立医学図書館（NLM）

Comparative Immunogenicity and Tolerance of Vaqta and Havrix

This open-label, randomized trial compares the [immunogenicity and tolerance] of two [inactivated hepatitis A vaccines], [Vaqta and Havrix], in adults aged [18-30 years]. The study evaluated the effectiveness of both vaccines in generating an immune response and assessed the incidence and severity of adverse reactions. The researchers found that both vaccines were [similarly immunogenic] but differed in their [local tolerance], with Vaqta demonstrating a [better safety profile] than Havrix. This research provides valuable insights into the comparative efficacy and safety of these two commonly used hepatitis A vaccines.

Navigating the Desert of Vaccination

This study underscores the importance of choosing the right vaccine for individual needs. Just as a camel selects the safest path across the desert, healthcare professionals must consider the specific characteristics of each vaccine to ensure optimal protection and minimize potential risks. This research provides valuable information for making informed decisions about hepatitis A vaccination.

Protecting the Herd: A Desert Oasis of Immunity

This research highlights the importance of vaccination in protecting individuals and communities from infectious diseases. Imagine a desert oasis, a haven of life and abundance amidst the harsh landscape. Similarly, vaccination creates a protective shield against disease, safeguarding our health and well-being. This research contributes to our understanding of vaccine efficacy and safety, helping to ensure the continued success of vaccination programs around the world.

Dr.Camel's Conclusion

This trial offers valuable insights into the comparative immunogenicity and tolerance of Vaqta and Havrix, reminding us that the desert of vaccination is vast and we must continually seek new knowledge and approaches to improve vaccine development and distribution.

Date :
  1. Date Completed 1999-07-27
  2. Date Revised 2019-07-28
Further Info :

Pubmed ID

10367952

DOI: Digital Object Identifier

10.1016/s0264-410x(98)00352-1

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.